Our top pick for
Beginners

Akorn Inc is a drug manufacturers-specialty & generic business based in the US. Akorn shares (AKRX) are listed on the NASDAQ and all prices are listed in US Dollars. Akorn employs 2,227 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $0.04 |
200-day moving average | $0.18 |
Wall St. target price | $2.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.82 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Akorn stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akorn's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Akorn's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $46.9 million.
The EBITDA is a measure of a Akorn's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $721.3 million |
---|---|
Gross profit TTM | $252.7 million |
Return on assets TTM | -0.94% |
Return on equity TTM | -231.8% |
Profit margin | -55.64% |
Book value | $1.86 |
Market capitalisation | $12 million |
TTM: trailing 12 months
We're not expecting Akorn to pay a dividend over the next 12 months.
Over the last 12 months, Akorn's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akorn's is 1.1428. This would suggest that Akorn's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Akorn, Inc. , a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.